We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

160 hedge funds and large institutions have $562M invested in LENZ Therapeutics in 2025 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 53 increasing their positions, 33 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 33

9.91% more ownership

Funds ownership: 102.17% → 112.08% (+9.9%)

4% less funds holding

Funds holding: 166 → 160 (-6)

11% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 56

48% less call options, than puts

Call options by funds: $2.74M | Put options by funds: $5.28M

59% less capital invested

Capital invested by funds: $1.36B → $562M (-$794M)

67% less funds holding in top 10

Funds holding in top 10: 9 → 3 (-6)

Holders
160
Holders Change
-6
Holders Change %
-3.61%
% of All Funds
1.95%
Holding in Top 10
3
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-66.67%
% of All Funds
0.04%
New
50
Increased
53
Reduced
33
Closed
56
Calls
$2.74M
Puts
$5.28M
Net Calls
-$2.53M
Net Calls Change
+$2.02M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$105M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$22.5M
3
IECM
Intrinsic Edge Capital Management
Illinois
+$16.6M
4
Millennium Management
Millennium Management
New York
+$15.7M
5
Franklin Resources
Franklin Resources
California
+$14.8M

Top Sellers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
-$50M
2
RI
RTW Investments
New York
-$40.2M
3
FLAM
First Light Asset Management
Minnesota
-$32.3M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$29.2M
5
SVCM
Saturn V Capital Management
Texas
-$17.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$4.33M +$7.9M +270,919 New
Goldman Sachs
27
Goldman Sachs
New York
$4.13M +$6.32M +216,666 +525%
RSCM
28
Rock Springs Capital Management
Maryland
$4.12M +$619K +21,233 +9%
DCM
29
Discovery Capital Management
Connecticut
$3.86M +$7.03M +241,300 New
Morgan Stanley
30
Morgan Stanley
New York
$3.73M -$1.83M -62,837 -21%
PM
31
Plustick Management
Virginia
$3.2M – – –
Skandinaviska Enskilda Banken (SEB)
32
Skandinaviska Enskilda Banken (SEB)
Sweden
$2.97M – – –
SA
33
Sovran Advisors
California
$2.9M +$1.55M +53,214 +50%
SAM
34
Silvercrest Asset Management
New York
$2.8M +$5.09M +174,692 New
TI
35
Trexquant Investment
Connecticut
$2.77M +$5.05M +173,183 New
HF
36
HRT Financial
New York
$2.74M +$4.14M +141,974 +484%
PCM
37
Prelude Capital Management
New York
$2.72M +$4.96M +170,224 New
Charles Schwab
38
Charles Schwab
California
$2.71M +$251K +8,596 +5%
Northern Trust
39
Northern Trust
Illinois
$2.59M -$98.2K -3,368 -2%
AIC
40
AWM Investment Company
New York
$2.4M +$4.37M +150,000 New
BOCH
41
Blue Owl Capital Holdings
New York
$2.4M +$4.37M +150,000 New
Ameriprise
42
Ameriprise
Minnesota
$2.19M +$2.37M +81,223 +146%
SM
43
Scoggin Management
New York
$2M -$2.91M -100,000 -44%
Bank of America
44
Bank of America
North Carolina
$1.84M -$6.83M -234,440 -67%
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$1.81M +$2.1M +72,208 +177%
WP
46
Woodline Partners
California
$1.6M +$2.91M +100,000 New
Nomura Asset Management
47
Nomura Asset Management
Japan
$1.55M +$1.54M +53,006 +121%
Wealth Enhancement Advisory Services
48
Wealth Enhancement Advisory Services
Minnesota
$1.4M -$3.56K -122 -0.1%
XT
49
XTX Topco
Cayman Islands
$1.37M +$2.5M +85,782 New
Citadel Advisors
50
Citadel Advisors
Florida
$1.29M -$9.29M -318,856 -80%
1
2
3 4 5

LENZ Hedge Fund Activity: Q4 2025 in Review

160 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2025, worth a combined $562M — down 59% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 56 funds closed out of LENZ and 50 opened new positions — a net loss of 6 holders — while 33 trimmed existing stakes and 53 added.

The largest buyer was Fidelity Investments, adding an estimated $105M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $50M sold.

  • 160 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2025, down from 166 in Q3 2025.
  • Funds reported $562M of LENZ Therapeutics stock for Q4 2025, down 59% quarter-over-quarter.
  • 50 funds opened new LENZ Therapeutics positions in Q4 2025 and 56 closed out, a net change of -6 holders.
  • The largest LENZ Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $105M added.
  • The largest LENZ Therapeutics seller in Q4 2025 was Paradigm Biocapital Advisors, an estimated $50M sold.

Based on aggregated 13F filings for Q4 2025.